Population-based insights on the cancer-alzheimer's disease link: leveraging blood-based biomarkers to uncover biological pathways
Active Grant Awarded
- Award ID
- R21AG104537
- Recipient
-
University Of Southern California UEI G88KLJR3KYT5
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $476,238
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date 10% complete
- Place of performance
- Los Angeles, CA 90089, USA
Award details come from USAspending.gov.
About this award
The National Institutes of Health's National Institute on Aging, within the Department of Health and Human Services, awarded Grant R21AG104537 to the University of Southern California on September 9, 2026, obligating $476,238 under the Aging Research program (CFDA 93.866). The award funds population-based research on the inverse relationship between cancer and Alzheimer's disease and related dementias (AD/ADRD), testing whether cancer-related factors associate with direct biological markers of AD and neurodegeneration. The work examines associations of incident cancer, cancer polygenic risk, and cancer treatments with these biomarkers. It draws on Health and Retirement Study data, including repeated cancer history assessments, genomic data, and Medicare claims-linked treatment information, and adds new assays of amyloid beta 42/40 ratio, phosphorylated tau-181 and tau-217, neurofilament light chain, and glial fibrillary acidic protein. The project period ends August 31, 2028, and the place of performance is Los Angeles, California 90089. The National Institute on Aging's program mission supports biomedical and behavioral research aimed at preventing and treating AD/ADRD.
Description
- Abstract
- Robust epidemiological literature shows an inverse relationship between cancer and alzheimer's disease and alzheimer's disease-related dementias (ad/ADRD), in which individuals with history of cancer are at least 10- 15% less likely to develop ad/ADRD than similar individuals without cancer history, but the reason is unknown. Careful methodological work demonstrates that spurious factors such as survival bias are unlikely to fully explain the relationship, suggesting plausible etiologic mechanisms involving shared biological pathways that work in opposite directions to yield carcinogenesis or neurodegeneration. Most epidemiologic work has evaluated clinical ad diagnoses or cognitive functioning, rather than direct biological markers of ad. The long-term goals of this research are to advance understanding of potential biological mechanisms that inversely relate cancer and ad risk. The overall objective of this application is to evaluate relationships of incident cancer and cancer-related factors with biomarkers for ad and neurodegeneration. The rationale for the proposed work is that a clear understanding of the relationship between cancer-related factors and ad biomarkers opens new doors for understanding etiology of ad, including testable mechanistic hypotheses leading to novel interventions. We leverage data from the large nationally representative health and retirement study, which includes repeated assessments of cancer history, genomic data, and medicare claims-linked treatment information, together with new assays of amyloid beta 42/40 ratio (AΒ42/40), phosphorylated TAU-181 and 217 (PTAU181, PTAU217), neurofilament light chain (NFL), and glial fibrillary acidic protein (GFAP). Specifically, we will examine associations of incident cancer (aim 1), cancer polygenic risk (aim 2), and cancer treatments (aim 3) with these new ad blood-based biomarkers. By linking population-based survey, genetic, and administrative data with sensitive molecular measures of ad pathology, this integrative design moves beyond single-explanation models toward a comprehensive understanding of how cancer may influence ad risk in the general population, and identifies explanatory mechanisms with translational potential. Insights from this work will open new avenues for research, from basic science testing of candidate mechanisms to clinical studies that translate findings into novel ad prevention and treatment strategies and inform cancer treatment decisions with implications for brain health.
Quick answers
Who received award R21AG104537?
R21AG104537 was awarded to University Of Southern California by National Institute on Aging (National Institutes of Health) on September 9, 2026.
How much is award R21AG104537 worth?
$476,238 has been obligated on R21AG104537.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award